About OptMed

A clinical-stage company developing specialty healthcare products

OptMed, Inc. is developing specialty healthcare products with an initial focus on an innovative line of surgical, biocompatible adhesives. The company's lead product is BondEase® Topical Skin Adhesive that combines a proprietary polymer (methylidene malonate) and an advanced delivery technology.

In addition, OptMed has initiated the development of products based on a genitourinary technology platform for the targeted, local delivery of diazepam (the generic form of the widely used drug, Valium®) for the treatment of disorders such as overactive bladder (OAB) and urolithiasis (kidney stones).

The company employs a flexible, capital-efficient, virtual business model to develop products generated by its platforms. The company's business strategy is to build value through product development and to commercialize its products through alliances or sale.
In December 2013, OptMed completed a 162-patient, multicenter, prospective, open-label, randomized clinical study to evaluate BondEase® Topical Skin Adhesive.